Loading clinical trials...
Loading clinical trials...
Phase 3 Study to Establish the Efficacy and Safety of a New Tablet Formulation and Dosing Regimen of Balsalazide Disodium Dosed Twice Daily in Achieving Clinical Improvement in Subjects With Mildly to Moderately Active Ulcerative Colitis After 8 Weeks of Therapy
Conditions
Interventions
5 ASA, enemas, suppositories, corticosteroids
Locations
66
United States
Birmingham Gastroenterology Associates
Birmingham, Alabama, United States
Spring Memorial Hospital
Mobile, Alabama, United States
Little Rock Diagnostic Clinic
Little Rock, Arkansas, United States
Advanced Clinical Research Institute
Anaheim, California, United States
Lovelace Scientific Resources
Beverly Hills, California, United States
Digestive Liver Disease Specialists, Medical Group
Garden Grove, California, United States
Start Date
December 1, 2005
Primary Completion Date
March 1, 2007
Completion Date
June 1, 2007
Last Updated
November 25, 2019
NCT06372613
NCT07550673
NCT07374471
NCT05739864
NCT06071312
NCT04338204
Lead Sponsor
Bausch Health Americas, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions